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Abstract
The American Thoracic Society Pediatric Core Curriculum updates clinicians annually
in pediatric pulmonary disease in a 3 to 4 year recurring cycle of topics. The 2019
course was presented in May during the Annual International Conference. An
American Board of Pediatrics Maintenance of Certification module and a continuing
medical education exercise covering the contents of the Core Curriculum can be
accessed online at www.thoracic.org.
K E YWORD S
lymphatic disorders, obstructive sleep apnea, pediatric sleep, pneumonia, pulmonary vascular
malformations, transplant complications
Control of breathing in children
Ryan Perkins and Eliot S. Katz
1 | INTRODUCTION
The respiratory control system regulates PO2, PCO2, and pH within
a narrow range, under conditions of changing state, airway
resistance, and energy expenditure. The central respiratory pattern
generator network is located in the brainstem and receives input
from the cortex, hypothalamus, lung, chest wall, extremities,
cardiovascular system, emotional centers, chemoreceptors (cen-
tral/peripheral), and the upper airway. The peripheral chemorecep-
tors provide considerable input in the seconds following a change in
PCO2, but central chemoreceptors play a larger role over periods of
minutes to hours.
2 | ANATOMY
The respiratory rhythm is produced by neural networks located in
medullary aggregations termed the Dorsal Respiratory Group and
Ventral Respiratory Group (VRG). The respiratory pattern generator
contains neurons in the VRG called the pre‐Botzinger complex. The
nucleus tractus solatarius (NTS) receives signals from the pre‐
Botzinger complex and afferent modulation from the periphery.
Following integration, signals then project to the upper airway and
respiratory muscles.1
Central chemoreceptors located on the ventral medulla are
sensitive to cerebrospinal fluid (CSF) acidity. CSF and arterial blood
are separated by the blood‐brain barrier preventing H+ and
bicarbonate equilibration but allowing CO2 diffusion. Ventilatory
drive output is inversely related to pH. Cerebral blood flow is an
important determinant of central CO2 sensitivity. Cerebral blood
flow and hypercapneic ventilatory drive are inversely related with
decreases in cerebral blood resulting in increased hypercapniec
ventilatory drive. Peripheral chemoreceptors in the carotid artery
and aortic arch, are sensitive to PaCO2, PaO2, and H
+ and provide
afferent signals allowing for breath‐by‐breath modulation.2
3 | PHYSIOLOGY
During wakefulness and non‐rapid eye movement (NREM) sleep, the
breathing pattern typically alternates inspirations and expirations
without pauses. Respiratory rate and tidal volume are adjusted to
maintain PCO2, PO2, and pH. Breathing is regulated by PaCO2, and to
a lesser extent by PaO2.
3
The ventilatory control system is modeled by its loop gain, which
is the relationship between the ratio of the ventilatory response
to a ventilatory perturbation. Respiratory loop gain includes: (a)
Controller gain: chemosensitivity: the output of respiratory pattern
generators in response to PaCO2 and PaO2. Chemosensitivity is
highest during wakefulness, intermediate during NREM sleep, and
lowest during REM sleep; (b) Plant gain: the magnitude of CO2
changes in response to ventilatory drive output reflecting the
efficiency of the lungs; (c) Mixing gain: the circulatory delay between
the lungs and peripheral chemoreceptors, thoracic blood volume, and
brain extracellular fluid volume, that contributes to ventilatory
overshooting and undershooting.
Homeostatic oxygen sensing is primarily performed by the
carotid body. The contribution of oxygen chemoreceptor input to
eupneic ventilation is demonstrated by the decrement in ventilation
in response to a single breath of 100% oxygen. Preterm infants,
term infants, and adults who were exposed to a single breath of
100% oxygen were noted to have reductions in their ventilation of
40%, 14%, 10%, respectively. This suggests that baseline oxygen
tension contributes variability to respiratory drive. Under normo-
capneic conditions, decreases in PaO2 between 100 to 50 torr
results in little increase in minute ventilation, but dramatically
increases as PaO2 declines below 50 torr. The increased ventilation
is counterbalanced by a decrease in PaCO2 which attenuates the
increased ventilation. The output of the respiratory pattern
generator temporarily increases hypoxemia resulting in increased
respiratory muscle stimulation.4
4 | SLEEP
In NREM sleep, ventilation is predominantly chemically controlled. At
sleep onset, PaCO2 increases and PaO2 decreases. In NREM sleep, the
emergence of an apneic threshold below eupneic PaCO2 predisposes
to ventilatory instability. During apnea, CO2 accumulates and
oxygenation decreases, leading to chemoreceptor‐induced ventila-
tory overshoot. An increase in PaCO2 above apneic threshold is
required to reinitiate breathing.5 In REM sleep, breathing is
influenced by REM processes that lead to irregular rhythm with
frequent pauses. Abrupt decreases in motor output to the upper
airway and decreased minute ventilation are observed.
Arousal refers to paroxysmal increases of electrocortical activity
during sleep, causing sleep fragmentation. There is a shift towards
the wakeful level of ventilatory responsiveness and minute ventila-
tion increases. This response far exceeds increases necessary to
reverse apnea, leading to relative hypocapnia with decreased upper
airway motor tone and facilitating obstructive cycling.6 Ventilatory
control instability is a major contributor to obstructive sleep‐
disordered breathing.7
5 | INFLUENCE OF EXERCISE
Exercise is accompanied by increases in oxygen utilization and CO2
production, with minimal change to PaCO2, PaO2, or H
+ until activity
levels exceed 60% of maximum. Below anaerobic threshold, steady
state matching of CO2 production and ventilation occurs rapidly.
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Minute ventilation increases linearly until ~60% of maximal work
level, when the production of lactic acid results in markedly increased




When ascending to high altitude, the decrease in barometric pressure
results in declines in alveolar and arterial oxygen tension. The initial
response to hypoxemia is increased ventilation followed by a decline
to a new baseline slightly above the eupneic minute ventilation.
During the next month, ventilation gradually increases leading to
PaCO2 reductions that potentially cross the apneic threshold during
sleep. Hypoxemia increases hypercapneic ventilatory response
(increases Controller Gain), narrowing the CO2 reserve during sleep
(the difference between newly reduced baseline PaCO2 and the
apneic threshold), and making apnea and periodic breathing more
likely. Over time, this lowers CSF PCO2 and ventilation until a new
set‐point is reached.9
7 | CONCLUSION
Control of breathing is a complex system that is modeled by the loop
gain, which reflects the ventilatory response to a ventilatory
perturbation. This system thus has the capacity to respond to
physiologic changes associated with sleep, exercise, and altitude.
Management of obstructive sleep apnea in
children
Maria L Castro‐Codesal and Joanna E MacLean
8 | INTRODUCTION
The pathophysiology of obstructive sleep apnea (OSA) in children is
multifactorial and heterogeneous.
9 | CLINICAL ASSESSMENT
Identification of children with OSA requires a careful review of
symptoms and recognition of risk factors (Table 1). Snoring,
though a hallmark, is insufficient to identify OSA. Symptoms that
may be informative include observed apneas, difficulty breathing
during sleep, daytime sleepiness, and inattentive or hyperactive
behavior. These symptoms reflect subjective measures of sleepi-
ness, behavioral impairment, and quality of life at diagnosis and
predict their improvement after treatment.10 Use of a screening
tool, such as the Pediatric Sleep Questionnaire, provides a
standardized way of assessing symptoms.10 Adenoid and/or
tonsillar enlargement are an important risk factors for OSA in
children; however not all children with adenotonsillar hypertrophy
have OSA,11 and removal of adenoids or tonsils may not be
curative in all children.12 Assessment for potential morbidity
associated with untreated OSA is an important factor in triaging
diagnostic testing and treatment decisions.
10 | DIAGNOSTIC TESTING
Polysomnography remains the standard for the diagnosis of OSA in
children though there is considerable need for more accessible
alternatives as access to polysomnography is limited or unavailable in
many areas. The polysomnographic diagnosis of OSA relies primarily
on the apnea‐hypopnea index (AHI) or the obstructive apnea‐
hypopnea index (OAHI) where an AHI ≥2 events/hour or OAHI ≥1
event/hour indicate OSA in children >1 year of age.12 These and
other polysomnographic variables do not correlate with baseline or
posttreatment measures of sleepiness, behavior, or quality of life,10
suggesting that current polysomnographic measures may not reflect
TABLE 1 Common risk factors and morbidity associated with
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OSA‐related morbidity and that polysomnography alone may not well
reflect severity of OSA.
Alternatives to polysomnography are used in settings where
polysomnography is limited or unavailable. A 2017 position statement
from the American Academy of Sleep Medicine concluded that home
sleep apnea testing is not recommended for the diagnosis of obstructive
sleep apnea in children.13 Continuous overnight oximetry recording is
more accessible though with multiple ways that the data can be
analyzed and reported. Oximetry derived oxygen desaturation index
(number of 3% or greater dips per hour of recording) of 2 events/hour
has a high specificity and positive predictive value for a polysomno-
graphic diagnosis of OSA but also a high false negative rate.14
Automated methods for the analysis of oximetry appear promising as
they allow the inclusion of multiple oximetry parameters.15 Both
magnetic resonance imaging and drug‐induced sleep endoscopy provide
information on the site of airway obstruction. However, these tests
require special expertise, and are best used selectively after considering
sedation risks.16-18 The search is still on for biomarkers of OSA and its
associated morbidity for use in diagnostic testing.
11 | TREATMENT
In otherwise healthy children aged 5 to 9 years with mild to moderate
OSA, there is moderate quality evidence that adenotonsillectomy
provides benefit in terms of quality of life, symptoms, behavior, and
improvement in polysomnography measures.19 Almost half of the same
group of children managed nonsurgically normalized polysomnographic
findings at 7 months follow‐up so the benefits of surgery vs watchful
waiting should be carefully considered; black race, obesity, and AHI
above 5 events/hour identified children less likely to normalize AHI
without adenotonsillectomy.19 Anti‐inflammatory medication, including
intranasal steroids, leukotriene receptor antagonists, and azithromycin,
may be effective in improving OSA symptoms and reducing AHI and
should be considered when surgery is not an option or not curative.20,21
The combination of intranasal steroids and leukotriene receptor
antagonist may provide benefit over either alone.22 Weight loss or
stabilization, while challenging, should be encouraged in children with
obesity.20 Noninvasive ventilation, including continuous and bilevel
positive airway pressure, has challenges with use but is effective in
reducing AHI.20 There is insufficient evidence to support or refute the
use of oral and functional orthopedic appliances for the treatment of
OSA in children; these treatment options may be considered in select
cases.23 Treatment decisions should be individualized with consideration
of surgical risks, and benefits as well as burdens of nonsurgical options.
12 | CONCLUSION
A careful review of symptoms and identification of risk factor is
needed to identify children with OSA. Polysomnography remains the
standard for the diagnosis of OSA in children. Treatment options
include surgery, medications, and noninvasive ventilation.
Complicated pneumonia
Nour Akil and Charles R. Esther, Jr
13 | INTRODUCTION
Community acquired pneumonia (CAP) remains an important cause
of morbidity and mortality worldwide.24 Although CAP generally
responds well to therapy with narrow spectrum antibiotics directed
against Streptococcus pneumoniae as the most common causative
organism,25 complicated pneumonia should be suspected if a child
with CAP has not responded to standard therapy within 48 to
72 hours, or when comorbidities such as immune deficiency or
chronic lung disease are present.26 Complicated pneumonia is
defined as the presence of one or more of the following complica-
tions: pulmonary necrosis, pleural effusion or empyema, lung abscess
and bronchopleural fistula.25,26 The incidence of complicated
pneumonia appears to be increasing over time.24
14 | DIAGNOSIS
The diagnosis and treatment of complicated pneumonia require
different strategies from uncomplicated CAP (Figure 1). Initial testing
F IGURE 1 Simplified algorithm for management of complicated
CAP. CAP, community acquired pneumonia; CT, computed
tomography; VATS, video assisted thoracoscopic surgery
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should include complete blood count with differential and inflamma-
tory markers, which allow monitoring of treatment responses that
can decrease duration of hospitalization and antibiotic courses.26,27
Guidelines also recommend obtaining blood cultures in cases of
complicated pneumonia,25 since bacteremia prevalence has been
found to be as high as 7%,28 although bacteremia alone does not
make a pneumonia complicated. Further microbiologic testing from
samples like sputum, bronchoalveolar lavage, and lung biopsy should
be pursued when feasible, since identification of the pathogenic
organism allows for tailored antibiotic treatment. Newer molecular
techniques such as polymerase chain reaction can increase the
likelihood of identifying the causative organism.26
Imaging is also recommended for evaluation of possible compli-
cated pneumonia, with a chest radiograph as the initial diagnostic
modality. If the chest radiograph suggests the presence of a
moderate or large pleural effusion, chest ultrasound is recommended
to confirm the presence of fluid as well as provide estimates of the
size of effusion and the presence of loculations.29 Chest CT with
contrast can be considered an alternative radiologic modality, but
ultrasound is preferred since CT does not provide superior diagnostic
information yet is more expensive and involves exposure to
radiation.29 However, contrast enhanced chest CT should be
considered if necrotizing pneumonia or lung abscess is suspected.
15 | TREATMENT
S. pneumoniae remains the most common identified pathogen in
complicated pneumonia (Table 2). However, the introduction of
pneumococcal conjugate vaccines (PCVs), particularly PCV‐13,
appears to have decreased the incidence of S. pneumoniae and
increased the likelihood of infection with other pathogens such as
Staphylococcus aureus.26,30 When a specific pathogenic organism has
not been identified, empiric treatment with a parenteral third
generation cephalosporin is recommended.25 If clinical features
suggest S. aureus infection (eg, necrotizing pneumonia), then addition
of vancomycin or clindamycin (based on local susceptibility patterns)
is recommended, with linezolid as a second‐line therapy (Table 2).
Addition of macrolide therapy should be considered when atypical
organisms such as Chlamydia pneumoniae or Mycoplasma pneumoniae
infection are detected by appropriate diagnostic testing (Table 2).
There is no consensus on the appropriate length of therapy for
complicated pneumonia, with expert recommendations favoring a
switch from parenteral to oral therapy after resolution of fever, with
a further 1 to 4 weeks of treatment.25,29 Longer courses of
intravenous antibiotic therapy do not appear to improve outcomes
and can be associated with increased complications.31
When parapneumonic effusions are present, drainage is recom-
mended unless the effusion is small and not contributing to
respiratory symptoms.25,29 Both chest thoracoscopic tube drainage
with fibrinolysis and video assisted thoracoscopic surgery (VATS) are
acceptable options, and patient preference and local expertise should
drive decision making.25,29 Evidence suggests that VATS may shorten
duration of chest tube placement, but studies vary as to whether
VATS improves other clinical outcomes such as length of stay, and
VATS remains more expensive.32 When chest thoracoscopic drainage
is performed, evidence suggests that addition of fibrinolytics
improves outcomes,33 although simple drainage alone can be
considered for free‐flowing effusions.25
16 | OUTCOMES
Perhaps the most important consideration when managing compli-
cated pneumonia in children is that mortality and long‐term
morbidity in previously healthy children is very low in developed
nations, regardless of the treatment strategy employed. Never-
theless, guidelines remain valuable to help reduce short term
morbidity, minimize risk, and promote antibiotic stewardship.
Although published guidelines on complicated pneumonia in children
are now several years old, recent research suggests that they are still
relevant.26,30,31 However, further studies are needed to help resolve
unanswered questions and ensure that guidelines remain applicable
as care changes with time, particularly introduction of effective
pneumococcal vaccines.
17 | CONCLUSION
The diagnosis and treatment of complicated pneumonia require a
specific algorithm (Figure 1), with the possible need for microbiologic
identification, additional imaging, and alternative treatment regi-
mens. Despite these challenges, mortality and long‐term morbidity
remain low in developed countries.
Approach to respiratory viruses in children
Jacob Kaslow and Toby C. Lewis.
TABLE 2 Common microbial etiologies of complicated pneumonia
and suggested treatments
Organism Antimicrobial treatmenta
Streptococcus pneumoniae IV 3rd generation cephalosporin
Streptococcus pyogenes IV 3rd generation cephalosporin
Staphylococcus aureus Add IV Clindamycin or Vancomycin or
add Linezolid (2nd line)
Consider rifampin combination therapy
Mycoplasma pneumoniae Add azithromycin
Chlamydia pneumoniae Add azithromycin
Viruses (except influenza) None
Influenza A/B Add Oseltamivir or Zanamivir
aShould be guided by susceptibility patterns and local antimicrobial
profiles and policies.
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18 | INTRODUCTION
Respiratory viral infections are a ubiquitous problem with known
geographic and seasonal patterns, which can cause a spectrum of clinical
disease depending on an individual’s distinctive immune condition and
environmental exposures.34 While most respiratory viral infections are
self‐limited and localize to the upper respiratory tract, about one‐third
of infants will also develop lower respiratory tract symptoms, which can
become severe. Approximately 80% of the estimated 2 million global
deaths due to respiratory infections between the ages of 0 and 5 years
are caused by viral pathogens. Since 2000, at least six viruses associated
with acute respiratory illness have been discovered, including viruses
now commonly associated with respiratory disease such as human
metapneumovirus.35 The suggested approach to respiratory viruses in
this section reflects the point of reference of a pulmonary subspecialist
assessing children with recurrent or underlying disease, rather than the
vantage of a general pediatrician who sees many more children who will
not have recurrent problems.
19 | DIAGNOSTIC TESTING
Most patients are typically diagnosed based on clinical presentation
and can be successfully managed with supportive care; thus, specific
diagnostic testing is not typically needed. Diagnostic testing may be
helpful for patients at highest risk for complications from viral
infections, such as those with chronic medical conditions, or for
children hospitalized when the cause of wheezing is unclear and
identifying a specific virus may help exclude other diagnostic
possibilities. Historically, the gold standard for diagnosis of respira-
tory viral infections was immunofluorescence assays and viral
culture, but these have been replaced with multiplex polymerase
chain reaction and nucleic acid amplification point of care testing, as
these convey improved sensitivity and specificity as well as reduced
resulting time.36,37
20 | PREVENTION
Prevention of respiratory viral infections primarily involves measures
to reduce exposure such as good hand hygiene and avoidance of
contact with other people with acute respiratory symptoms.
Annual vaccination against influenza (flu) is universally recom-
mended in the United States for all children 6 months and over, with
particular emphasis on children with underlying respiratory condi-
tions. Egg allergy is no longer considered a contraindication to
receiving influenza vaccine. The flu vaccine has been shown to reduce
influenza‐related hospitalizations and deaths in children.38 Three
forms of flu vaccine are available: an inactivated influenza vaccine, a
recombinant influenza vaccine, and a live attenuated influenza
vaccine (LIAV). LIAV is approved for the 2018 to 2019 season,
though it is generally not recommended for those with underlying
lung conditions and there has been past concern the LAIV has
reduced effectiveness compared to the inactivated form.39 A
universal vaccine that would not require annual re‐immunization is
in development but is not yet commercially available.
There are no available vaccines against respiratory syncytial virus
(RSV). Passive immunoprophylaxis with the RSV monoclonal antibody
palivizumab is recommended by the American Academy of Pediatrics
for infants in the first year of life born before 29 weeks gestation,
with chronic lung disease or with hemodynamically significant
congenital heart defects. There is indeterminate evidence to support
a recommendation for use in patients with other underlying chronic
disease such as cystic fibrosis, Down Syndrome, neuromuscular
weakness, or those with immune suppression.40
Immunization against other childhood viral infections with
possible respiratory manifestations, such as measles and varicella,
are readily available as part of routine childhood vaccination
programs.
21 | TREATMENT
The foundation of treatment of respiratory viral infections is
supportive care with emphasis on hydration, secretion clearance
from the nose, and respiratory support. Bronchodilators and systemic
steroids are not recommended for healthy patients without under-
lying respiratory conditions, though there may be a narrow spectrum
of patients with severe disease where an empiric trial of these
medications might be considered. Viral infections may trigger
exacerbations of underlying conditions, such as asthma or cystic
fibrosis, necessitating intensified disease‐specific therapy. Aeroso-
lized ribavirin is not routinely recommended for RSV infections due
to inability to demonstrate consistent efficacy, although it may be
considered in patients with severe, life‐threatening disease.41
Antiviral medications can be helpful for treatment of influenza.
Oseltamivir (Tamiflu) has been shown to decrease symptom length
by approximately 24 hours in patients with influenza infection
although results have not been reproducible in patients with
underlying lung disease.42
22 | INNOVATIONS
A universal flu vaccine with antigenic peptide sequences common to
a variety of influenza viruses is currently in phase three clinical trials
in Europe and phase two clinical trials in the United States. These
trials are currently limited to the adult population.
There is a recent increase in RSV vaccine development with
more than 28 therapies in predevelopment and at least 17 in
clinical development. However, a widely available vaccine is not
expected to be available for at least 5 to 10 years.43 Additional
methods to prevent RSV infection are being explored including
a maternal vaccine that is expected to complete phase three
clinical trials in 2020.
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There has been significant difficulty in developing both a vaccine
and therapy for rhinovirus, due to a variety of antigenically distinct
types. Efforts to develop vaccines for other respiratory viruses such
as human metapneumovirus have not shown adequate effectiveness.
23 | CONCLUSION
Respiratory viral infections in children are usually self‐limited but
can progress to more severe lower respiratory tract infections.
Diagnostic testing is indicated in limited clinical situations, and
prevention is focused on hand hygiene, immunization, and immu-
noprophylaxis against RSV in high‐risk populations. Treatment
options are also limited, although there are ongoing efforts focused
on vaccine development.
Lymphatic disorders of the respiratory tract in
children
Katie A. Krone and Annabelle Quizon
24 | INTRODUCTION
Disorders of the lymphatic system comprise various phenotypes due
to defects in development, maturation, and/or function of lymphatic
vessels. This clinical spectrum includes, but is not limited to, lymphatic
malformations (LM), generalized lymphatic anomaly (GLA), and
hereditary as well as sporadic forms of primary lymphedema. Clinical
features depend on the structures involved and degree of functional
compromise (eg, airway obstruction, dysphagia, phrenic nerve palsy).
Recent advances in the genetic characterization of lymphatic disorders
reveal mutations affecting proteins involved in the RAS/MAPK and
PI3K/AKT pathway, which may account for inherited forms.44,45
Nomenclature is evolving as phenotypic distinctions are identified
(Table 3) as detailed by the International Society for the Study of
Vascular Anomalies in 2018.44,45
25 | CLINICAL PRESENTATION
Common LM, previously referred to as cystic hygroma and
lymphangioma, occur in lymphatic‐dense areas, with the majority
affecting the head and neck.46,47 There exist three morphologic types
of common LM: macrocystic, microcystic, and combined. Macrocystic
lesions are often large multilocular masses located below the
mylohyoid muscle.48 Microcystic lesions usually appear as noncom-
pressible masses located above the mylohyoid muscle and are often
more infiltrative.49 Most common LM present within the first 2 years
of life and increase in size over time. Symptoms are dictated by the
involved structures. The anterior neck is a classic location;
approximately 10% extend into the mediastinum.50 Intrapulmonary
LM are rare.51 Complications that may adversely impact the airway
include tracheal compression and oropharyngeal infiltration. Chylous
pleural and pericardial effusions may develop.
GLA, previously termed lymphangiomatosis, is characterized by
multifocal LM affecting thoracic and abdominal viscera as well as
bone.52 Chylothorax is frequent. A recently described subset of GLA,
Kaposiform lymphangiomatosis (KLA), may present with hemorrhagic
lymphatic effusions, hemoptysis, coagulopathy and variable throm-
bocytopenia; this entity portends a poor prognosis, particularly in the
setting of pulmonary involvement. Progressive osteolysis of cortical
bone distinguishes Gorham‐Stout disease from GLA.53,54 This disease
is also known as “vanishing bone disease” and characterized by LM
affecting a single or multiple bones and often neighboring soft tissue.
Channel type disorders result from failure to clear lymph due to
channel obstruction, dilation, or dysmotility, causing chylothorax,
pulmonary lymphangiectasia, and edema of the extremities or body
wall. Acquired progressive lymphatic anomaly or so called progres-
sive lymphangioma is a rare benign LM appearing as a solitary plaque
on the trunk and limbs possibly as response to injury.55 Primary
lymphedema leads to abnormal accumulation of interstitial fluid as a
result of developmental defects affecting maturation and function of
the lymphatic system. The lower extremities are commonly affected.
Disease may be primary or associated with syndromic disorders, such
as Turner and Nonne‐Milroy syndromes.56,57 Genetic mutations
underlie many types of primary lymphedema as shown in Table 3.
TABLE 3 Classification of lymphatic malformations44,45 (revised in
2018)
Lymphatic malformations (LM) Gene




Generalized lymphatic anomaly (GLA)
Kaposiform lymphangiomatosis (KLA)
LM in Gorham‐Scout Disease
Channel type LM
“Acquired” progressive lymphatic anomaly
Primary lymphedema
Nonne‐Milroy syndrome FLT4/VEGFR3




Primary lymphedema with myelodysplasia GATA2




Microcephaly with or without
chorioretinopathy, lymphedema, or mental
retardation syndrome
KJF11
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26 | DIAGNOSIS
Diagnosis of lymphatic disorders is based primarily on suggestive
history and physical examination.58 Prenatal detection can be
achieved with ultrasound or fetal magnetic resonance imaging
(MRI).59,60 Doppler ultrasound and MRI are important initial
modalities to morphologically characterize the malformation,
determine extension, and plan appropriate treatment.61,62
Given the lymph component, increased signal on T2‐weighted
images is characteristic, with gadolinium helping to differentiate
LM from venous malformation. In cases in which intralesional
bleeding has occurred, a fluid‐fluid level may be seen due to the
layering of blood and proteinaceous material. Computed tomo-
graphy is valuable in assessing involvement of adjacent bony
structures. Other modalities, such as MR‐lymphangiography,
overcome technical limitations of traditional contrast lymphan-
giography in infants and small children. Whereas lymphoscinti-
graphy remains the gold standard for evaluation of lymph flow,
newer modalities such as near‐infrared fluorescence lymphatic
imaging allow for evaluation in real‐time without exposure to
radiation or sedation. Histologic confirmation is rarely necessary
but should be considered if imaging is equivocal or if malignancy
or KLA are suspected.
27 | MANAGEMENT
Treatment is individualized and should be delivered by an experi-
enced multidisciplinary care team.63 Given the potential for cosmetic
deformity and encroachment on vital structures, it is essential that
management is determined without delay. Approaches include
observation, surgery, sclerotherapy, radiofrequency ablation (RFA),
laser therapy, and medical management (Table 4). While observation
may be appropriate in select cases, combining multiple modalities is
often necessary.64 Previously, surgical resection was the mainstay of
treatment. However, high rates of recurrence prompted identifica-
tion of alternative management strategies,64 and impending airway
compromise is the primary indication for prompt surgical interven-
tion. Sclerotherapy is now considered first‐line therapy, and
commonly used sclerosing agents include OK‐432 (Picibanil),
doxycycline and bleomycin.65 Surgical resection to debulk a lesion
may be followed by sclerotherapy to remove residual disease. RFA
has shown promise in microcystic LM affecting the oropharyngeal
cavity. In addition, the use of medications has evolved in recent
years. Sildenafil, a phosphodiesterase‐5 inhibitor, has demonstrated
mixed treatment response,66,67 whereas sirolimus, a mammalian
target of rapamycin (mTOR) inhibitor in which mTOR is a down-
stream target of the PI3K pathway, has shown benefit for most
TABLE 4 Treatment of lymphatic malformations
Treatment Mechanism Application Adverse effects
Observation Select cases without cosmetic




Surgical resection Complete or partial resection Surgical complications






Sclerotherapy Inflammatory Macrocystic LM May require repeated
OK‐432 (Picibanil) reaction secondary treatments
Doxycycline to sclerosant and Soft tissue edema




Radiofrequency ablation Transmission of Microcystic LM Complications related to




Laser therapy Vaporization of tissue Debulk oropharyngeal LM Scarring
Cutaneous LM Hypopigmentation
Medical management
Sildenafil Phosphodiesterase‐ Cystic LM Nausea
5 inhibitor Orbital LM
Sirolimus mTOR inhibitor GLA, KLA, GSD Possible increased risk of
infections
Propanolol β‐adrenergic ? Benefit in mixed Hair loss
receptor antagonist vascular malformations
Abbreviations: AEs, adverse effects; GLA, generalized lymphatic anomaly; GSD, Gorham‐Stout disease; KLA, Kaposiform lymphangiomatosis; LM,
lymphatic malformations; mTOR inhibitor, mammalian target of rapamycin inhibitor.
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lymphatic disorders.68-70 Randomized controlled trials are needed to
guide optimal management.
28 | CONCLUSION
Ongoing research is essential in understanding the genetic under-
pinnings of lymphatic disease, identifying predictors of clinical
course, and quantifying therapeutic response. Scientific discovery
of defective signaling pathways will translate to development of
novel molecular targets for treatment. New information will further
inform revisions in nomenclature and guide evidence‐based evalua-
tion and management strategies.
Pulmonary vascular malformations in children
Ryne Simpson and Dan Benscoter.
29 | INTRODUCTION
Vascular anomalies are relatively common among children and can
affect capillaries, arteries, veins, or lymphatics.
30 | CLASSIFICATION
The International Society for the Study of Vascular Anomalies
developed an updated classification system in 2018 to provide
consistent terminology for clinicians and researchers.71,72 Vascular
anomalies are classified as proliferative vascular tumors or vascular
malformations. Although most vascular anomalies provide little risk to a
child’s health, pulmonary complications can occur and include airway
obstruction, hemorrhage, intrapulmonary shunting, and thrombosis.
Because signs and symptoms associated with these anomalies may be
subtle, early recognition and appropriate management is critical to
prevent potentially devastating consequences.
Vascular malformations arise due to congenital errors of vessel
morphogenesis. Malformations tend to grow with the child, in
contrast to proliferative vascular tumors, which grow out of
proportion to the child and have a predictable growth cycle.
Vascular malformations may grow rapidly due to hormonal
stimulation or trauma.73 The genetic basis for vascular malforma-
tions is an emerging field with mutations having been recently
discovered for numerous lesions.74 Vascular malformations are
further classified into four groups (Table 5); however, vascular
malformations can also be designated as slow‐flow or fast‐flow
lesions. Slow‐flow lesions include venous, capillary, and lymphatic
malformations. Fast‐flow lesions are primarily arteriovenous
malformations (AVMs). This differentiation has important clinical
implications, as slow‐flow lesions are more likely to be complicated
by thrombosis whereas fast‐flow lesions are more likely to be
complicated by hemorrhage. Vascular malformations may directly
impact respiratory physiology or have associated complications
affecting the respiratory system.
31 | PULMONARY ARTERIOVENOUS
MALFORMATIONS
AVMs arise due to an error in vascular development during
embryogenesis and result in shunting of blood from the arterial to
venous circulation. Although many children with pulmonary AVMs
are asymptomatic, the right‐to‐left shunt may result in dyspnea with
exertion, cyanosis, or hemoptysis. Larger AVMs also convey a risk for
paradoxical emboli to the brain due to the lack of the capillary bed’s
filtering function.
Contrast echocardiography is a highly sensitive test for detecting
pulmonary AVMs in children.75 Multidetector computed tomography
provides extensive assessment of the vascular architecture of
pulmonary AVMs and can be used to plan treatment. Transcatheter
embolotherapy is the mainstay of treatment for pulmonary AVMs,
though controversy exists in the timing of treatment in children.76
Indications for embolization include symptomatic lesions and AVMs
with feeding arteries greater than 2 to 3mm in diameter which
present a greater risk for neurologic complications. There is risk for
reperfusion or development of pulmonary collateral vessels after
embolotherapy.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal
dominant disorder characterized by mucocutaneous telangiectasias,
epistaxis, visceral AVMs and a family history of HHT. Up to 60% of
children with HHT may have a pulmonary AVM, many of which
develop after an initial negative screen.77 Although recommenda-
tions on screening patients with HHT exist only for adults,78 the high
prevalence of pulmonary AVMs in children suggests that screening
should also be performed at a young age.
32 | VASCULAR MALFORMATIONS
ASSOCIATED WITH OTHER ANOMALIES
Several syndromes associated with vascular malformations convey
an increased risk for respiratory complications. Klippel‐Trenaunay
syndrome (KTS) is a rare syndrome due to complex capillary‐
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lymphatic‐venous malformations, resulting in overgrowth of soft
tissue and bone with limb hypertrophy. Patients with KTS may
have ectatic veins connected to central veins, resulting in a
predisposition to venous stasis and increased risk for deep vein
thrombosis and pulmonary embolism.79 Proteus syndrome is an
asymmetric overgrowth syndrome associated with complex
vascular malformations that can result in thromboembolism due
to stasis in the affected limb. Some children with Proteus
syndrome also develop bullous lung malformations. Children
with CLOVES syndrome (congenital lipomatosis, vascular
malformations, epidermal nevi, skeletal/scoliosis abnormalities)
may have central or thoracic phlebectasia increasing their risk for
pulmonary embolism.
33 | AIRWAY INFANTILE HEMANGIOMAS
Infantile hemangiomas are proliferative lesions as opposed to true
vascular malformations. Airway infantile hemangiomas are typically
asymptomatic at birth. A child with a subglottic hemangioma may
develop stridor or a croup‐like cough during the proliferative phase,
typically within the first 6 months of life. The presence of multiple
cutaneous hemangiomas in the head and neck region increases the
risk of having an airway hemangioma. Propranolol has been shown to
be an effective treatment for airway infantile hemangiomas;
however, some children may still require surgical intervention.80
Clinicians must remain vigilant following treatment as rebound
growth can occur after discontinuation of propranolol.81
34 | CONCLUSION
Pulmonary vascular malformations in children include AVMs and
malformations associated with other anomalies. Infantile hemangio-
mas represent proliferative lesions, rather than vascular malforma-
tions. Diagnosis and management vary by specific condition.
Pulmonary complications of hematopoietic cell
transplant
David R. Spielberg and Ernestina Melicoff.
35 | INTRODUCTION
Hematopoietic cell transplant (HCT) is an accepted therapy for
various hematologic malignancies, nonmalignant diseases, and solid
tumors. Despite advances in the past decades, pulmonary complica-
tions remain a significant limitation to success.82
Predisposing factors of pulmonary complications include HCT
type, autologous vs allogeneic; conditioning regimen, chemotherapy
with or without radiation; and pre‐transplant pulmonary disease.83
36 | ASSESSMENT
Pretransplant respiratory assessment includes laboratory studies
(blood gases, serum chemistries assessing acid‐base status, and
complete blood count), electrocardiogram, spirometry,84 lung vo-
lumes, diffusing capacity of the lung for carbon monoxide (DLCO),
and 6‐minute walk testing.82 Chest computed tomography (CT)
use should be based on history and clinical findings. Based on the
frequency of abnormal findings, routine sinus CT imaging may be
justified.85 A number of risk scores have been developed, but none
has been validated in children. The lung function score combines the
forced expiratory volume in 1 second (FEV1) and DLCO, estimating
the risk of mortality and acute respiratory failure.86 The
pre‐transplantation assessment of mortality score utilizes eight
clinical factors to predict mortality within the first 2 years.87
Pulmonary complications can be divided into those that are
infectious and noninfectious. Their clinical diagnosis can be facilitated
by the well‐known timeline of the most common diseases; early
complications occur within 100 days from HCT, while late complica-
tions take place beyond 100 days.83 Patients can present with
various signs of respiratory tract disease.82,83 Noninvasive tests can
differentiate between upper respiratory tract infections and pul-
monary complications. A basic evaluation consists of blood culture,
sputum culture, nasopharyngeal swabs, urinary antigens, and chest
radiograph.88 If symptoms are severe or there is no resolution, a
chest CT is recommended. Flexible bronchoscopy for bronchoalveo-
lar lavage (BAL) is considered a valuable tool in patients with lung
infiltrates on imaging. A recent study showed that early broncho-
scopy (<5 days) had higher diagnostic yield than late bronchoscopy
(78 vs 23%).88 Open lung biopsy can provide an accurate
histopathological diagnosis, but due to the associated morbidity,
careful patient selection is necessary.89
37 | IDIOPATHIC PNEUMONIA SYNDROME
Idiopathic pneumonia syndrome (IPS) is a common acute noninfec-
tious complication, with an incidence reported to be around 20% in
children.83 Clinical manifestations include dyspnea, non‐productive
cough, and hypoxemia. Pulmonary function testing reveals a
restrictive physiology. The diagnosis of IPS requires BAL to be
negative for infection. Histopathology of biopsies demonstrates
interstitial pneumonia and diffuse alveolar damage. IPS treatment
remains supportive, and prognosis is poor in patients who require
mechanical ventilation. Other early complications observed in
children include veno‐occlusive disease, pulmonary edema, and
pulmonary hemorrhage.82,83
38 | INFECTIOUS COMPLICATIONS
Infectious complications appear during the different phases post‐
HCT: bacterial infections predominate the pre‐engraftment phase,
MOORE ET AL. | 1889
fungal infections are seen in those with delayed engraftment, and
more than two‐thirds of HSV‐seropositive patients develop stoma-
titis. Early CMV reactivation can be seen in 50% to 80% of
seropositive allogeneic recipients. Ganciclovir and high dose anti‐
CMV IgG are part of the treatment and have led to significant
reduction in incidence and mortality.83 Post‐engraftment, invasive
Aspergillus (IA) occurs in 15% of allogeneic HCT recipients, and
symptoms include fever, pleuritic chest pain, dyspnea, and hemop-
tysis. Chest CT findings in IA include the halo sign and air‐crescent
sign, which are characteristic but not diagnostic. Aspergillus species
can be isolated from BAL in 30% to 50% of cases.
39 | BRONCHIOLITIS OBLITERANS
In addition to infectious and acute post‐HCT complications, the lung
is subject to chronic sequelae of HCT in the setting of chronic graft‐
vs‐host disease (GVHD). This typically manifests in the lungs as
Bronchiolitis Obliterans (BO) or Bronchiolitis Obliterans Syndrome
(BOS), the distinction depending upon the presence of biopsy‐proven
disease. An initial National Institutes of Health consensus project was
reported in 2005 and updated in 2014.90 Spirometry is key to the
diagnosis of BOS for two reasons: (a) airflow obstruction defines the
physiology of the disease; and (b) spirometric changes can present
before symptoms, thus providing an opportunity for early interven-
tion. CT is an important supportive diagnostic tool, with well‐
described findings in BOS, but it is not necessary for the diagnosis if a
patient has known chronic GVHD of other organ systems. Most
importantly, infection must be excluded in the evaluation of a patient
with suspect lung GVHD—both because of the ability of infection to
mimic the clinical presentation and because of risks of initiating
additional immunomodulatory therapies in the setting of infection.
BOS treatment focuses on quelling the immune response. Data
on treatment protocols are extremely limited; only a few randomized
clinical trials exist, and no studies have prospectively compared
different regimens in a head‐to‐head fashion. A number of clinical
trials are ongoing. Therapies range from inhaled corticosteroids to
various systemic immunomodulatory therapies, including extracor-
poreal photopheresis.91
40 | CONCLUSION
Pulmonary complications remain a significant concern after hemato-
poetic cell transplant. Infectious complications appear during the
different stages posttransplant, and BAL is required to rule out
infection before the diagnosis of IPS and BO.
Pulmonary complications of solid organ
transplant
Cadence A. Kuklinski and Joshua A. Blatter
41 | INTRODUCTION
Pulmonologists can help transplant teams to anticipate pulmonary
complications based on a patient’s history. Patients with evidence
of asthma, for example, may require alterations to their main-
tenance medication plans in the months preceding transplant, with
some patients benefiting from short courses of oral corticoster-
oids.92 Avoiding tobacco smoke exposure is particularly important
in the transplant setting, as secondhand smoke exposure has been
associated with perioperative complications and reduced health‐
related quality of life.93 The association between sleep pathology
and transplant morbidity has not been confirmed, although
obstructive sleep apnea is associated with airway complications
in surgical patients.
42 | ASSESSMENT
At some transplant centers, candidates may undergo a formal
assessment of frailty before transplant, and frail patients under-
going transplant have been shown to have worse outcomes.94 Six‐
minute walk testing is useful in predicting transplant mortality,
and not just among lung transplant recipients. Even in the absence
of a formal frailty assessment, pulmonologists can highlight
characteristics that are preoperative red flags, such as decondi-
tioning and malnutrition.
Pulmonary function testing (PFT) can help stratify the
pulmonary risk of transplant candidates. PFT abnormalities are
relatively common both before (eg, decreased forced vital capacity
and forced expiratory volume in 1 second)95 and after (eg
decreased diffusion of carbon monoxide)96 heart transplant. PFTs
do not dependably predict postsurgical pulmonary complica-
tions.97 Nevertheless, obtaining pretransplant PFTs with both
spirometry and lung volumes can identify existing, previously
unknown abnormalities and can be used for comparison if there
are respiratory complications after transplant.
There may be relatively low yield in obtaining basic chest
imaging before transplant. However, a chest radiograph may help
identify previously unknown abnormalities, such as lymphadenopathy,
that may demand further evaluation before surgery. While not
part of a routine evaluation, polysomnogram, echocardiography,
and right‐heart catheterization may be obtained if clinically
indicated.
43 | INFECTION
After transplant, the likelihood of pulmonary complications will
vary by allograft type, as well as by the length of time following
transplant. Kidney transplant recipients, for example, may have
relatively low risk of pulmonary infection, due both to the nature
of the surgery and to the relatively light immunosuppression
needed to sustain the allograft.98 Longer surgery duration itself is
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associated with the development of postoperative pulmonary
complications such as atelectasis, pneumonia, and respiratory
failure.97 Among all transplant recipients, common community‐
acquired infections are the most likely causes of mild illness as
time passes and immunosuppression is lightened.99 While the
possibility of pneumocystis jiroveci pneumonia (PJP) requires
vigilance in all solid‐organ transplant recipients, PJP is substan-
tially less likely in patients who have consistent adherence to a
PJP prophylaxis care plan or are years removed from trans-
plant.100 Tuberculosis is also an important consideration in the
immunosuppressed population, and both tuberculin skin testing
and interferon‐gamma release assay testing may be useful in an
infectious workup.101
CMV‐ and EBV‐mediated disease can occur either early or late
after transplant. CMV infections can occur even in patients who
adhere to a prophylaxis plan and can be considered in patients with a
wide array of pulmonary and gastrointestinal symptoms. Posttrans-
plant lymphoproliferative disorder (PTLD) is associated with B cell
proliferation due to EBV infection in immunosuppressed hosts. In
suspected EBV+PTLD, the EBV viral load is often elevated.
44 | INTERVENTIONS
Pulmonologists can also identify interventions to prevent or reduce
pulmonary complications after solid organ transplant. Patients with
neuromuscular weakness are likely to benefit from mechanical
insufflation/exsufflation,102 and patients with limited mobility due
to postoperative pain may benefit from airway clearance. Pain
management should strike a balance between respiratory depression
and sufficient analgesia and not reduce participation in postoperative
pulmonary rehabilitation. Although nutritional support has not been
shown to reduce the incidence of pulmonary complications, there is
an established association between low albumin levels and pulmon-
ary morbidity. Moreover, initiation of nasogastric feeding can help to
protect patients with dysphagia from developing pulmonary compli-
cations after surgery.97
45 | CONCLUSION
The pulmonologist plays an important role in evaluating complica-
tions following solid organ transplant. Assessment includes careful
review of history, pulmonary function testing before and after
transplant, and imaging as clinically indicated. Infectious risks vary by
allograft time and length of time following transplant. Therapeutic
interventions may prevent or reduce pulmonary complications.
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